4th EUROPEAN BIOTECH & MEDTECH INVESTOR DAY

by France Biotech
MISSION

Our mission is to improve the prognosis of patients with brain diseases by increasing the permeability of cerebral blood vessels to allow therapeutic molecules such as antibodies, pathway inhibitors, chemotherapies or enzymes to reach effective concentrations in brain.

TECHNOLOGY

We have developed the SonoCloud, a patented clinical stage intracranial implant that temporarily and repeatedly opens the blood-brain barrier (BBB) on demand using low intensity pulsed ultrasound.

COMPETITION

SonoCloud is a first-in-class solution to safely and repeatedly increase concentrations of therapeutic agents in the brain.

ALLIANCES/PARTNERSHIPS

Partnering with CarThera allows pharmaceutical companies or biotech to increase therapeutic effects and extend indications of their agents to brain disorders with limited regulatory hurdles and low costs.

UPCOMING CATALYSTS

Preliminary efficacy results of our SonoCloud treatment in combination with carboplatin for recurrent GBM
Launch of an investigator sponsored trial with the SonoCloud in combination with anti-PD1 & CTLA4 for brain metastases from melanoma
Outcome of ongoing discussions with pharmaceutical companies for other indications

MARKET FIGURES

Revenues 2017: No revenues
Date of IPO: Private company
COMPANY SUMMARY

CARTHERA

NAME OF THE CEO
Frederic SOTTILINI

ADDRESS
Institut de Cerveau et de la Moelle Epiniere
Hopital Pitie Salpetriere
47 bd de l’hopital – CS21414
75646 PARIS cedex 13 - FRANCE

EMAIL
contact@carthera.eu
frederic.sottilini@carthera.eu
http://www.carthera.eu

TARGETED MARKET
SonoCloud is intended to be used as an add-on procedure to investigational or commercialized pharmaceutical treatments of brain diseases like glioblastoma (GBM), brain metastases, rare diseases, Alzheimer’s or other neurodegenerative diseases.

PRIVATE COMPANY CREATION DATE
2010

MANAGEMENT TEAM
CEO: Frederic SOTTILINI
Chairman: Dominique COSTANTINI
CMO: Carole DESSEAUX
CTO: Francois LACOSTE

SHORTHOLDERS

INDICATIONS

<table>
<thead>
<tr>
<th>CLINICAL PIPELINE</th>
<th>INDICATIONS</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recurrent GBM</td>
<td>FIM</td>
<td>Phase 1/2a</td>
<td>Phase 2b/3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alzheimer’s Disease</td>
<td>Exploratory Trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brain metastases from melanoma</td>
<td>Phase 1/2a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pediatric rGBM</td>
<td>Exploratory Trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PRECLINICAL PIPELINE</th>
</tr>
</thead>
<tbody>
<tr>
<td>GlioTex Immuno/Chemotherapy</td>
</tr>
<tr>
<td>MD Anderson CC Targeted/Immuno-therapy</td>
</tr>
<tr>
<td>Northwestern U Chemotherapy</td>
</tr>
</tbody>
</table>